



# Canadian Urological Association guideline: Management of ureteral calculi – Abridged version



Jason Y. Lee, MD<sup>1</sup>; Sero Andonian, MD<sup>2</sup>; Naeem Bhojani, MD<sup>3</sup>; Jennifer Bjazevic, MD<sup>4</sup>; Ben H. Chew, MD<sup>5</sup>; Shubha De, MD<sup>6</sup>; Hazem Elmansy, MD<sup>7</sup>; Andrea G. Lantz-Powers, MD<sup>8</sup>; Kenneth T. Pace, MD<sup>1</sup>; Trevor D. Schuler, MD<sup>6</sup>; Rajiv K. Singal, MD<sup>1</sup>; Peter Wang, MD<sup>9</sup>; Michael Ordon, MD<sup>10</sup>

<sup>1</sup>Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada; <sup>2</sup>Division of Urology, Department of Surgery, McGill University Health Centre, Montreal, QC, Canada; <sup>3</sup>Department of Urology, Université de Montréal, Montreal, QC, Canada; <sup>4</sup>Division of Urology, Department of Surgery, Western University, London, ON, Canada; <sup>5</sup>Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; <sup>6</sup>Division of Urology, Department of Surgery, University of Alberta, Edmonton, AB, Canada; <sup>7</sup>Urology, Northern Ontario School of Medicine, Thunder Bay, ON, Canada; <sup>8</sup>Department of Urology, Dalhousie University, Halifax, NS, Canada; <sup>9</sup>London Health Sciences Centre, Western University, London, ON, Canada; <sup>10</sup>Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada

**Reviewer:** John Dushinski, MD

Southern Alberta Institute of Urology, Calgary, AB, Canada

**Cite as:** Lee JY, Andonian S, Bhojani N, et al. Canadian Urological Association guideline: Management of ureteral calculi. *Can Urol Assoc J* 2021;15(12):383-93. <http://dx.doi.org/10.5489/cuaj.7652>

Full-text published online August 21, 2021; available at [cuaj.ca](http://cuaj.ca) and [cua.org](http://cua.org)

See related commentary on page 394

## Introduction

Globally, the prevalence of urolithiasis is steadily increasing, and though some regional variability exists, contemporary estimates report up to 10–12% of men and 7–8% of women now suffer from nephrolithiasis.<sup>1-3</sup>

Renal colic is one of the most frequent and expensive emergency department (ED) presentations.<sup>1,2</sup> A study comparing renal colic management patterns in two Canadian cities identified widely varying trends in care, with admission rates as high as 60%, and surgical intervention rates over 50%. Though early intervention has been purported to allow patients to return back to normal life sooner, it appeared early intervention led to increased subsequent ED visits, re-admissions, and secondary procedures.<sup>4</sup> Another study looking at costs associated with management of acute renal colic found that an initial trial of non-surgical management was associated with lower indirect costs.<sup>5</sup> The aim of this Canadian Urological Association (CUA) guideline is to provide evidence-based consensus recommendations on various aspects relevant to the management of ureteral stones; the major topics included were conservative management, medical expulsive therapy, shockwave lithotripsy

(SWL), ureteroscopy (URS), and special clinical scenarios (e.g., pregnancy, pediatrics).

## Methods/guideline development process

Separate reviews of the literature were performed for each of the major topics. English-language publications were identified from PubMed/Medline, with a focus on recent publications since our last CUA guideline document on ureteral stones published in 2015.<sup>6</sup> The 2011 University of Oxford Centre for Evidence-Based Medicine Levels of Evidence grading system was used to evaluate the level of evidence of recommendations included in the document.<sup>7</sup> All recommendations were based on expert review of the literature and represent the consensus of all authors of this guideline document.

## I. Conservative management of ureteral stones

Non-operative management remains a reasonable first-line approach for most patients presenting with ureteral stones. A 2010 meta-analysis of 37 studies demonstrated that 38–71% of symptomatic ureteral stones <4 mm would pass spontaneously.<sup>8</sup> As well, looking at the placebo control arms of several large randomized controlled trials (RCTs) evaluating the efficacy of medical expulsive therapy (MET), spontaneous passage rates range from 40–80% for stones <10 mm.<sup>9-11</sup> Clearly, an initial course of conservative management seems reasonable for many.

The urologist is often called upon in the setting of a suspected “septic stone” — conservative management is not

an option in this setting. With a sufficient index of suspicion, early goal-directed therapy, including blood and urine cultures, broad-spectrum intravenous antibiotics, resuscitation, and source control is paramount. Decompression of an obstructed pyelonephritis reduces mortality<sup>12</sup> and avoiding delays can prevent prolonged hospital admissions.<sup>13</sup> The method of drainage should be tailored to the patient's clinical scenario and stone characteristics, as well as to the available resources at each center.<sup>14,15</sup> In the only prospective, randomized trial, patients presenting with a fever  $>38^{\circ}\text{C}$ , leukocytosis, and obstructing stone  $<15$  mm were randomized to either a ureteric stent or a nephrostomy tube (NT).<sup>16</sup> There were no differences in any clinical outcome evaluated, including time-to-defervescence, duration of hospital stay, and resolution of obstruction. Other studies have also found that timely decompression is paramount, regardless of method.<sup>17-19</sup> It is generally agreed that definitive treatment should not be undertaken until the obstructed system has been decompressed and the infection adequately treated. Although, there is no strong evidence as to how long to wait after initial treatment, one study recommends a minimum of seven days before definitive treatment.<sup>20</sup>

While patients with true urosepsis (life-threatening organ dysfunction caused by a dysregulated response to a genitourinary [GU] infection)<sup>21</sup> are more easily identified, accurately diagnosing pre-septic patients with a concomitant urinary tract infection (UTI) and an obstructing stone may not be as clear. Irritative lower urinary tract symptoms, hematuria, and pro-inflammatory urine/blood markers have led to inconsistent interpretation about the presence of infection and ultimately antibiotic use.<sup>22</sup> Many patients are inappropriately given antibiotics and there is an opportunity to improve clinical practice and antibiotic stewardship with some continued medical education initiatives.

Acute kidney injury (AKI) is present in approximately 6% of patients presenting with renal colic.<sup>23</sup> When significant renal impairment accompanies ureteral stones, early decompression or definitive therapy may mitigate further deterioration. Early intervention may also be indicated if the patient with a ureteral stone presents with intractable symptoms (pain, nausea, etc.) or significant frailty/comorbidities.

There is limited data supporting early surgical intervention rather than a period of initial conservative therapy, with one RCT demonstrating that early ureteroscopic management ( $<12$  hours after ED admission) led to similar stone-free and complication rates but lower rates of postoperative stenting.<sup>24</sup> Two RCTs looking at early SWL ( $<48$  hours) vs. delayed SWL (2–7 days) demonstrated earlier time to stone-free status, fewer required treatments, and perhaps lower complications in the early SWL arms.<sup>25,26</sup> Importantly, these studies had a high risk of bias, highlighted by the fact that spontaneous stone passage rates in the delayed intervention arms of these RCTs was only 0–5.4%.

**Recommendation: Many patients with ureteral stones can initially be managed non-operatively, as spontaneous passage rates are high, particularly for smaller stones ( $<5$  mm). Close followup is necessary for those being managed conservatively, to ensure spontaneous stone passage or to decide upon the need for timely intervention (level 2, strong recommendation). Obstructive pyelonephritis requires early goal-directed therapy, including timely decompression in an antegrade or retrograde fashion, whichever method is most expedient (level 2, strong recommendation).**

## Imaging

Use of computed tomography (CT) scans have increased by over 10-fold in recent years,<sup>27</sup> being performed in 90% of those diagnosed with urolithiasis in the acute setting, whereas ultrasonography (US) is used in less than 7% of these patients.<sup>28</sup> There is evidence to suggest patient gender may impact initial imaging modality selected.<sup>29,30</sup> A large, randomized trial comparing initial imaging modalities for renal colic presentations in the ED found most clinical outcomes were equivalent between US and non-contrast CT (NCCT) imaging, recommending initial US given the lack of radiation exposure.<sup>28</sup> In this RCT, US performed by radiologists, compared to point-of-care US (POCUS), were less likely to result in followup CT scans, but did increase visit times within the ED.<sup>31</sup> While POCUS is convenient, it is more operator-dependent and consulting teams often have no images or formal report to review. Details found on a NCCT are often, but not always, required for definitive stone management and followup, particularly for complex scenarios.

Supplementing US with kidney-ureter-bladder (KUB) X-rays can enhance the sensitivity of detecting a ureteral stone. Studies demonstrate that combining these modalities results in sensitivity ranging from 79–100%, and specificity up to 100%.<sup>32</sup> One study also demonstrated that the addition of a formal KUB X-ray, even when CT scout images were available, improved followup diagnostic accuracy.<sup>33</sup> Obtaining a KUB X-ray at the time of a diagnostic imaging in the ED is useful for not only determining stone composition, but also to track the progress of stone passage in followup.

Reduced-dose NCCT scans have been shown to maintain sensitivities and specificities from 90–97%, while preserving enough detail to identify alternate diagnoses. When assessing for stones specifically, body mass index (BMI) has been shown to be less of a concern, with  $>95\%$  diagnostic accuracy and radiation doses  $<3.7$  mGy regardless of BMI.<sup>34</sup> Though dual-energy CT scans have shown utility in identifying uric acid stone composition,<sup>35</sup> there is little additional benefit in the acute setting, as obstructing stones are not typically treated with dissolution therapy.

Overall, while adhering to as-low-as-reasonably-achievable (ALARA) radiation exposure principles, the patient's

age, pregnancy status, stone history, and preceding exposure to ionizing radiation should be considered whenever ordering imaging for non-life-threatening indications. An over-reliance on CT imaging has been identified and should be addressed in our practice patterns.

**Recommendation: US with KUB X-ray should be considered the initial modality of choice for acute ureteral stones. Judicious use of CT scans, preferably low-dose, provides valuable information for management decisions (level 1, strong recommendation). While often omitted, the utility of a KUB X-ray at the time of presentation is very important for future followup and decision-making regarding definitive treatment options (level 4, expert opinion).**

### Discharge planning

#### *Medical expulsive therapy (MET)*

Recently, several large RCTs<sup>11,36,37</sup> failed to show improved stone passage rates or reduced analgesic requirements when using alpha-blockers for MET. However, several published meta-analyses<sup>38-40</sup> suggest overall benefit of MET for ureteral stones. Subgroup analysis data suggest this benefit may be mainly for larger (5–10 mm), distal ureteral stones.<sup>36,37,40-42</sup> A Cochrane review of 67 studies analyzed all studies, specifically looking at lower- and higher-quality studies. The higher-quality, placebo-controlled studies showed a benefit with MET (relative risk [RR] 1.16, 95% confidence interval [CI] 1.07 to 1.25), a decrease in hospitalizations (RR 0.51, 95% CI 0.34–0.77), and no significant changes in the need for intervention.<sup>43</sup>

#### *Analgesia*

Moving away from a reliance on opioids in acute care patients with renal colic is important and these patients have been found to do well with non-opiate analgesia.<sup>44</sup> In one study, 1500 adult acute care patients were randomized to intramuscular diclofenac, intravenous morphine, or intravenous paracetamol. At 30 minutes, non-steroidal anti-inflammatories (NSAIDs) were more effective in reducing pain by 50% compared to morphine, with no adverse events.<sup>45</sup> Another randomized trial showed protocolled non-opioid analgesia could reduce opioid requirements during initial presentation if first- and second-line interventions included NSAIDs and intravenous lidocaine. However, opioid-sparing approaches were associated with higher rates of repeat visits to the ED.<sup>46</sup> Discharge prescriptions can vary significantly based on the patient population and comorbidities. Accounting for important patient characteristics (e.g., post-traumatic stress disorder, anxiety/depression, chronic pain syndromes) when prescribing analgesia for acute renal colic is also important.<sup>47,48</sup>

#### *Forced hydration*

While there is clear utility in re-hydrating hypovolemic patients with significant nausea and vomiting, or in those with a suspected pre-renal AKI, intravenous (IV) hydration for the sole purpose of forced stone passage is not supported by the literature and should be avoided.<sup>49</sup>

**Recommendation: The role of MET in promoting spontaneous passage is controversial, but the current literature suggests if there is any benefit, it is for larger (5–10 mm) ureteral (distal) stones. The advantages and disadvantages of MET should be discussed with the patient in a shared decision-making process (level 1, strong recommendation). The use of opioid-sparing analgesic regimens has been shown to be efficacious and opioids for management of renal colic should be minimized; patient education is paramount (level 1, strong recommendation). Forced IV hydration for the purposes of stone expulsion is not recommended (level 1, moderate recommendation).**

### Renal colic followup

Unfortunately, neither resolution of symptoms nor patient reports of successful passage of obstructing ureteral stones is always confirmatory. One study demonstrated that 6.2% of patients reporting passage of a symptomatic ureteral stone had persistent obstruction on followup CT imaging.<sup>50</sup> Another study demonstrated that resolution of pain was only 79.7% sensitive and 55.8% specific for successful passage of a ureteral stone, based on followup US and KUB X-ray imaging.<sup>51</sup> As such, followup imaging to ensure passage of an obstructing ureteral stone is suggested. The ideal imaging modality of choice remains uncertain, but one study found that 38% of patients with a persistent ureteral stone, confirmed on ultra-low-dose CT, had neither hydronephrosis on CT nor a visible stone on the CT scout image.<sup>52</sup>

Data suggest the majority of patients that will pass ureteral stones spontaneously will do so within approximately one month of presentation.<sup>11,33-34</sup> Examining the literature on long-term renal damage and ureteral obstruction, it is difficult to elucidate an objectively safe or unsafe duration of observation for a ureteral stone where no imperative indication for treatment exists; the data is mainly from animal studies and usually involves a complete obstruction model. While degree and duration of obstruction are clearly important, other factors unique to each patient also need to be considered: poor baseline renal function, older age, male gender, and presence of certain comorbidities (e.g., diabetes) have been associated with increased risk of chronic kidney disease.<sup>53,54</sup>

**Recommendation: Resolution of symptoms and patient-reported stone passage after a bout of renal colic do not always confirm passage of an obstructing ureteral stone.**

**Followup imaging is recommended to confirm stone passage** (*level 3, strong recommendation*). **The recommended duration of conservative management is unique to each patient, with multiple factors to be considered. Surgical intervention should likely be considered if a patient has not passed an obstructing ureteral stone after 4–6 weeks** (*level 5, moderate recommendation*).

## II. Shockwave lithotripsy

Despite the advances in ureteroscopes and laser technologies, SWL remains a first-line treatment option for ureteral calculi. SWL outcomes can be directly influenced by case selection, surgeon technique, and modifiable parameters to enhance safety and maximize successful outcomes. Much of the data for SWL outcomes is derived from patients with renal calculi, but these findings should be generalizable to ureteric stones, particularly for those in the upper ureter, where renal parenchyma is included in the shockwave path.

### Clinical factors affecting SWL treatment success

#### Composition

The majority of stones are composed of calcium oxalate and most will fragment well with SWL treatment. There are certain stone compositions, such as cystine, pure calcium oxalate monohydrate, and brushite, that are more resistant to SWL and may be better served by URS management.<sup>55</sup> Uric acid stones, while fragile in the face of SWL, require either the use of ultrasound or pyelography (intravenous or retrograde) for targeting during SWL.

#### Stone density

Stone density, as measured on NCCT scan in Hounsfield units (HU), has been shown to predict successful SWL outcomes. A crude surrogate for composition, a linear relationship exists between increased stone density and poor stone fragmentation with a threshold of 1000 HU, above which stones are less likely to be successfully fragmented.<sup>56–60</sup> The variation coefficient of stone density (VCSD), which is a measurement of stone heterogeneity on CT scan and reflects the crystal architecture of the stone, has been reported as a novel predictor of SWL success and may outperform HU as a predictor of success; however, further study in this measurement would be useful.<sup>61</sup>

#### Skin-to-stone distance (SSD)

A longer SSD has been associated with reduced treatment success for SWL for renal<sup>62–67</sup> and ureteral stones,<sup>65</sup> with SSD greater than 10 cm often associated with decreased stone-free rates (SFRs).

**Recommendation: Stone size, location, composition, density, and SSD can help counsel patients regarding the success rates of SWL treatment. Known uric acid, cystine, and brushite stones are likely best treated with URS** (*level 4, moderate recommendation*). **Patients with ureteral stones with a density >1000 HU or SSD >10 cm have lower SFR with SWL** (*level 2, strong recommendation*); **shared decision-making with patients is important to balance the availability, morbidity, and efficacy of SWL vs. URS.**

### Optimizing treatment outcomes

#### Dose escalation/pause

Gradually increasing SWL energy up to optimal dose allows for better patient accommodation to the sensation of treatment and, for upper ureteral stones, reduces renal injury by inducing renal vasoconstriction.<sup>68–72</sup> An alternative strategy is to pre-treat with a series of low-energy shocks, then pause treatment for a short period of time before resuming at higher-energy levels.<sup>68</sup>

#### Number of treatments

If SWL is not successful, it can be repeated, but the incremental benefit of more than two treatments for the same ureteric stone is small.<sup>73,74</sup> The optimal time interval between SWL treatments is unclear but can be short (2–3 days) for mid and distal ureteral stones.

#### Treatment rate

Several randomized trials have indicated that a lower shock rate can improve stone fragmentation, particularly for stones larger than 1 cm. The optimal treatment rate is not clear, however, studies suggest that SWL at 60–90 shocks/minute leads to better fragmentation than 120 shocks/min, particularly for larger stones.<sup>75–83</sup> Most studies were performed with renal calculi, however, improved outcomes have been demonstrated for upper ureteric stones as well.<sup>76</sup>

#### Number of shocks

The optimal number of shocks has not been definitively established but requires balancing treatment efficacy with adverse effects, particularly renal damage. For upper ureteral stones, the recommended shock rate range is 2000–3500, but manufacturer's guidelines should be closely considered.<sup>74</sup> For mid to distal ureteric stones, where the renal parenchyma is not affected by SWL energy, treatment can safely be carried out up to 4000 or more shocks.<sup>74</sup> Some studies have assessed the efficacy and safety of increasing the number of shockwaves per session to >4000.<sup>84,85</sup>

**Recommendation: Patients with upper ureteric stones should initially receive low-energy shocks, with gradual voltage escalation up to maximum energy** (*level 2, strong*

recommendation). If unsuccessful, repeat SWL can be considered but more than two treatments to the same ureteric stone has little incremental benefit and URS should then be considered (level 4, moderate recommendation). Patients with upper ureteric stones >1 cm or those selected for retreatment after initial failed SWL, should be treated at a rate <120 shocks/minute for optimal fragmentation (level 1, strong recommendation). An adequate number of shocks (2000–4000 for most lithotripters) should be administered to ensure adequate treatment of ureteric stones (level 4, weak recommendation). A higher number of shocks may result in improved SFR, but data is limited to make this a recommendation for routine practice.

### Alpha-blockers

Alpha-blockers (most commonly tamsulosin) have been studied to assess their impact on SWL outcomes in multiple RCTs and meta-analyses.<sup>86-95</sup> Meta-analyses have shown improved SWL success rates,<sup>89,94-96</sup> time to stone passage, risk of steinstrasse,<sup>93-96</sup> and need for auxiliary procedures.<sup>93</sup> A recently published Cochrane systematic review demonstrated routine alpha-blocker therapy may result in improved stone clearance, less need for auxiliary treatments, fewer major adverse events, and a reduced stone clearance time.<sup>97</sup> Additional benefits with respect to pain and analgesic use are also of interest.

### Stenting

Routine pre-SWL stenting is not necessary and does not improve the success rate or passage of fragments.<sup>98-101</sup> In fact, having a stent may impede the passage of fragments following SWL and does not appear to decrease the risk of steinstrasse or infection,<sup>100-104</sup> with the possible exception of steinstrasse risk for stones >2 cm.<sup>100</sup> Stents may be beneficial for obstructing stones, if relief of obstruction is warranted prior to treatment (e.g., obstruction with infection, renal failure, intolerable pain) and prior to SWL for stones in a solitary kidney.<sup>105</sup>

**Recommendation: Alpha-blockers (e.g., tamsulosin) should be prescribed after SWL for ureteral stones to improve treatment success rates (level 1, moderate recommendation). Ureteral stents do not improve SFR after SWL and do not reduce the risk of steinstrasse or infection following SWL for most patients (i.e., stones <2 cm) (level 1, moderate recommendation).**

## III. Ureteroscopy

Modern URS is a mainstay in the surgical treatment of ureteral stones worldwide. As a result of advancements in technology in recent decades, URS can be safely performed with high SFR and relatively low complications.

### Preoperative alpha-blockers

The use of alpha-blockers prior to URS appears to improve intraoperative outcomes and patient SFR. A recent systematic review and meta-analysis comprising of 12 RCTs and 1352 patients evaluated alpha-blocker use before planned URS for the management of ureteral calculi.<sup>106</sup> With a median preoperative use of one week, a 61% risk reduction in need for ureteral dilatation was observed. Furthermore, the use of preoperative alpha-blockers significantly improved SFR (RR 1.18, 95% CI 1.11–1.24,  $p < 0.00001$ ), reduced operative time by an average of six minutes ( $p = 0.004$ ), and decreased patient hospital stay ( $p = 0.001$ ). Whether one week of use is optimal or simply convenient for patients was not defined. Larger, more appropriately powered RCTs may provide further direction regarding the efficacy of preoperative alpha-blockers for URS of ureteral stones.

**Recommendation: Preoperative alpha-blockers may improve intraoperative and postoperative outcomes for patients undergoing URS. However, the optimal duration of preoperative alpha-blocker therapy is still uncertain (level 1, moderate recommendation).**

### Postoperative imaging

The goal of postoperative imaging is to assess for residual stone burden and screen for ongoing obstruction. Residual stone fragments may lead to additional stone-related episodes and surgical intervention.<sup>107,108</sup> Some authors have concluded that in the setting of uncomplicated URS, routine postoperative upper tract imaging is not necessary.<sup>109</sup> Instead, they have recommended postoperative imaging indications include chronic stone impaction, significant ureteral trauma, prior renal impairment, endoscopic evidence of stricture, and postoperative pain or fever. However, silent obstruction, described as asymptomatic, persistent, postoperative obstructive hydronephrosis, has been shown to occur at a rate of 1.9–10% following URS, highlighting the importance of routine postoperative imaging.<sup>109-111</sup> The mean interval from URS to possible development of ureteral stricture is estimated to be 13 months.<sup>112</sup> While NCCT is the best modality for identifying both residual fragments and postoperative obstruction, the effective dosage of radiation and the cost of this modality have prevented its routine use post-URS. Rather, a combination of US and KUB X-ray are typically used to detect obstruction and stone-free status.

**Recommendation: An US ± KUB X-ray is recommended following URS for ureteral stones. (level 4, strong recommendation). In complicated cases, further imaging with NCCT can be performed.**

## Ureteral access sheaths

Ureteral access sheaths (UAS) can offer numerous advantages during URS. They allow for rapid and multiple re-entries into the upper tract, potentially reducing damage to the ureteroscope. UAS can also enhance visibility, decrease intrarenal pressure, and allow for drainage and elimination of dust and stone fragments.<sup>113</sup> The proper selection of UAS size is crucial to balancing URS outcomes. Excessive force should never be applied when using UAS. Most of the literature on UAS use during URS is related to renal stones.

In a prospective cohort analysis of 2239 patients, no significant difference in SFR was seen whether a UAS was or was not used during flexible URS (75.3% vs. 50.4%,  $p=0.604$ ).<sup>114</sup> However, in subgroup analysis of stones  $\geq 10$  mm, SFRs were significantly higher in the UAS group (84.9% vs. 81.5%,  $p<0.01$ ). One systematic review revealed no significant difference in operative times, SFRs, or intraoperative complications with UAS use.<sup>115</sup> A critical drawback of these systematic reviews is that a substantial number of studies did not use NCCT to determine true SFR and as a result, the impact of UAS use on SFR after URS remains unclear.

In a study of 2239 patients treated with flexible URS, no significant difference in ureteral injuries was reported in patients treated with UAS in comparison to those without UAS.<sup>114</sup> Grades of ureteral injuries related to UAS were reported as low-grade injuries involving the mucosa in almost half of patients and high-grade lesions involved smooth muscle layer in 15% of patients.<sup>116</sup> Importantly, endoscopically detected high-grade ureteral lesions following UAS insertion do not appear to result in an increased rate of stricture.<sup>117</sup>

**Recommendation: Current evidence suggests UAS use for ureteral stones has no significant impact on SFR nor on intraoperative complications (level 2, moderate recommendation), but may improve visualization, reduce intra-renal pressures, and facilitate fragment removal (level 4, strong recommendation).**

## Stenting

Ureteral stent placement prior to elective URS can facilitate UAS and ureteroscope insertion. In a recent prospective study of rigid and flexible ureteroscopes, the ureter was inaccessible in 8% of cases, necessitating the placement of a ureteral stent and delaying definitive treatment.<sup>118</sup> Some studies have demonstrated no clear advantage in SFR nor complication rate with routine preoperative stenting,<sup>119,120</sup> while others have shown routine pre-URS stenting was associated with a higher SFR for larger stones.<sup>121-123</sup>

The impact of post-URS stenting on SFR is not clear and meta-analyses have shown conflicting results. One recent

meta-analysis found that stenting did not improve SFR nor reduce late postoperative complications after routine URS.<sup>124</sup> Conversely, in another meta-analysis of 22 RCTs, the SFR was significantly better in the stented group (95% CI 0.34–0.89;  $p=0.01$ ).<sup>101</sup> In terms of the impact on stricture rate, a meta-analysis of 14 trials and 1652 patients demonstrated that post-URS stenting likely does not reduce stricture rates at 90 days (RR 0.58, CI 0.23–1.47).<sup>125</sup> Conversely, use of a stent has been shown to reduce unplanned medical visits post-URS.<sup>125-127</sup> Following UAS use, routine ureteral stenting seems to be beneficial in reducing pain and unplanned medical visits.<sup>128,129</sup>

Nonetheless, there are scenarios where routine post-URS stent placement is advisable: suspected ureteric injury or stricture, solitary kidney, and in a patient with renal impairment.

The evidence is not clear on whether use of a stent post-URS impacts opioid use,<sup>125,130</sup> but urinary symptoms have been demonstrated to be significantly worse with stent use.<sup>101,124,126,131</sup> Studies have demonstrated beneficial effects of various medications (e.g., alpha-blockers, anticholinergics, B-agonists) to ameliorate stent-related urinary symptoms.<sup>132,133</sup>

There is no consensus regarding the optimum duration of postoperative stenting. In an animal model, there were no histological ischemic changes in the ureteral wall 72 hours post-UAS insertion, suggesting that three days may be sufficient.<sup>134</sup> On the other hand, Paul et al compared ureteral stent dwell times of three vs. seven days and found that removal at three days was linked to a higher probability of obstruction-related adverse events (23% vs. 3%).<sup>135</sup>

**Recommendation: Routine pre-URS stenting is not necessary but may facilitate UAS insertion and improve SFRs in patients with larger stones (level 2, weak recommendation). Routine stenting after uncomplicated URS is likely unnecessary (level 2, strong recommendation) but stent placement after UAS use is warranted (level 3, weak recommendation). Stent-related symptoms following URS may be ameliorated with alpha-blocker and/or anticholinergic medications (level 2, moderate recommendation). If access to the ureteral stone is complicated or impossible, placement of a stent and repeat URS is the safest option (level 5, strong recommendation).**

## IV. Comparing treatment outcomes – SWL vs. URS

### Stone-free rate

Previously published literature comparing SWL vs. URS for ureteric calculi, which focused largely on efficacy and safety, guided the development of the 2015 CUA guideline recommendations. Since then, several other studies have been published, including some important data on cost-effectiveness

and patient-reported outcomes. Due to the significant variation and heterogeneity of the techniques used to perform SWL and URS, it is difficult to make clear recommendations based on published literature.

For upper ureteric stones, a randomized trial of semirigid URS compared to SWL for stones <2 cm showed similar SFR (86.6% vs. 82.2%) at three months.<sup>136</sup> Those undergoing SWL had significantly higher re-treatment rates but after re-treatment, the need for subsequent auxiliary treatments was similar (21.1% vs. 17.7%,  $p < 0.5$ ). When the groups were substratified by stone size, URS produced a higher SFR for stones 1–2 cm (85.4% vs. 78.4%), though this was not statistically significant. Complication rates were also statistically similar (11.1% vs. 6.6%,  $p = 0.21$ ).

When dealing with distal ureteral stones, URS has traditionally been thought to produce superior results to SWL. However, several studies have demonstrated similar SFR between SWL and URS, with the caveat that SWL often required more than one treatment to achieve that same SFR.<sup>137–140</sup> A systematic review published in 2017 found that there was a better SFR with URS at four weeks, but this was comparable between groups at three months.<sup>141</sup> There were fewer re-treatments with URS, but higher complication rates. In terms of radiation doses to patients, one study showed equal amounts of radiation used for ureteral stones whether treating with URS or SWL.<sup>142</sup>

Costs can vary from region to region for each modality; an American study found that for ureteral stones  $\leq 1.5$  cm, the equivalency point for cost efficacy was when the SFR for SWL was <60–64% or if the chance of URS success was >57–76%.<sup>143</sup> For these situations, URS was found to be more cost-effective in an American system. A British cost-efficacy study was undertaken according to their National Institute for Health and Care Excellence (NICE) guidelines<sup>144</sup> and they concluded that for ureteral stones <1 cm, URS would be more costly even if SWL was only 40% efficacious.

**Recommendation: SWL produces similar SFR to URS for ureteral stones, albeit with a higher re-treatment rate and lower complication rate (level 1, strong recommendation). While local/regional cost models need to be considered, SWL may be a more cost-effective option for ureteric stones (level 4, weak recommendation).**

### Patient-reported outcomes

Ureteral stones can have a significant impact on the health-related quality of life (HRQOL) of patients.<sup>145–149</sup> Both SWL and URS have been found to have significant impacts on kidney stone patients' quality of life.

Overall, patients with ureteral stones are satisfied with their treatment choice approximately 50% of the time and there is no difference in treatment satisfaction correlated

to the selected modality (SWL vs. URS).<sup>150–152</sup> However, in one study specifically examining distal ureteric calculi, it was determined that more patients were satisfied with URS (n=113; 94.2%) compared to SWL (n=74; 80.4%) ( $p = 0.002$ ).<sup>153</sup>

Regarding HRQOL, the main HRQOL outcomes affected by SWL and URS are the physical functioning, social functioning, and pain domains on the 36-item Short Form Health Survey (SF-36).<sup>154,155</sup> A study comparing the HRQOL between patients who received SWL to those who received URS using the SF-36, found that patients who received URS scored worse than those who received SWL due in part to the higher analgesic requirements and longer hospital stay after URS compared to SWL, which was mainly attributed to the use of a ureteral stent.<sup>156</sup> Interestingly, the improved HRQOL for SWL over URS extended beyond the short-term and persisted at six months of followup, despite the higher SFR with URS. In contrast, a study compared the impact of URS vs. SWL on the HRQOL of patients with proximal ureteral stones and found that although there was no difference in change in HRQOL for patients with stones <10 mm, patients who underwent SWL for proximal ureteral stones >10 mm scored significantly lower on their SF-36.<sup>157</sup> Finally, a systematic review examined how ureteric calculi influence HRQOL and patient treatment preference.<sup>158</sup> A number of studies were reviewed, however, overall URS and SWL were both found to significantly impact SF-36 results similarly.

**Recommendation: Overall, there is similar patient satisfaction between SWL and URS for the treatment of ureteric calculi, but SWL has been found to have slightly better HRQOL outcomes, due primarily to the avoidance of a ureteral stent (level 2, moderate recommendation).**

### V. Special clinical considerations

Full-text discussion for this section is available in the online version of this guidelines document (at [cua.org](http://cua.org) and [cuaj.ca](http://cuaj.ca)), and we encourage readers to reference the document in full. For brevity, only recommendation statements have been included herein.

#### Anti-coagulation

**Recommendations: SWL and antegrade URS are contraindicated in patients with uncorrected coagulopathies. When the risk of holding antiplatelet or anti-coagulants outweigh the benefits, proceeding with URS while a patient is anti-coagulated is an acceptable option (level 2, moderate recommendation).**

## Antegrade management of ureteral stones

**Recommendations: Percutaneous antegrade URS should be considered in the treatment of stones in patients with urinary diversion and select large, impacted proximal ureteral stones, especially when prior retrograde URS has failed (level 4, strong recommendation).**

## Ureteral stones in children

**Recommendation: Ultrasound is the first-line diagnostic modality used in children with suspected ureteral stones. This may be coupled with a KUB X-ray to increase accuracy. Low-dose NCCT may be used in certain situations (level 3, strong recommendation). A trial of passage with/without MET is recommended for children with smaller (<5 mm) stones (level 2, strong recommendation). SWL is a safe and effective option for ureteral stones in children (level 2, strong recommendation). If ureteral dilation is required, passive dilation is preferred (level 4, moderate recommendation). It is recommended that ureteroscopes <8 French be used for URS in children (level 4, moderate recommendation).**

## Pregnancy

**Recommendation: First-line diagnostic testing for stones in pregnancy is US, but low-dose NCCT or magnetic resonance imaging (MRI) (without gadolinium in the first trimester) can also be used (level 3, strong recommendation). Obstructing ureteral stones in pregnancy can be managed conservatively in the absence of suspected or confirmed urinary infection (level 3, moderate recommendation). In pregnant patients presenting with signs of sepsis, antibiotics and urinary decompression via a NT or ureteral stent are of primary importance; consultation with the obstetrics team is recommended. URS with laser lithotripsy is safe in pregnancy; however, SWL is contraindicated in pregnancy (level 2, strong recommendation).**

**Competing interests:** Dr. Lee has received a speaker honorarium from Baxter. Dr. Bhojani has reviewed new products for Boston Scientific and participated in WATER 2, an Aquablation multi-institutional clinical trial supported by Procept. Dr. Chew has been a consultant for Auris Robotics, Bard Medical, Boston Scientific, and Olympus; has been a lecturer for Boston Scientific, Coloplast, Cook Medical, and Olympus; received a study grant from Boston Scientific; received a fellowship salary from Cook Medical; and participated in clinical trials supported by Boston Scientific and Cook Medical. Dr. Elmansy has received payment from Boston Scientific, Clarion Medical Technologies/AccuTech Medical Technologies, and Janssen; and received speaker honoraria and a travel grant from Lumenis. Dr. Pace has received support for a fellowship and annual lectureship from Cook Urological. The remaining authors report no competing personal or financial interests related to this work.

**Acknowledgement:** The authors would like to thank Simon Czajkowski, MSc (Phys), MBE, for his assistance in collating and synthesizing the many references in this document. They would also

like to thank Robin Parker, MLIS, PhD(c), for her assistance in conducting the literature search for the section on SWL.

## References

1. Scales CD, Smith AC, Hanley JM, et al. Prevalence of kidney stones in the United States. *Eur Urol* 2012;62:160-5. <https://doi.org/10.1016/j.eururo.2012.03.052>
2. Sarokin I, Mamoulakis C, Miyazawa K, et al. Epidemiology of stone disease across the world. *World J Urol* 2017;35:1301-20. <https://doi.org/10.1007/s00345-017-2008-6>
3. Raheem OA, Khandwala YS, Sur RL, et al. Burden of urolithiasis: Trends in prevalence, treatments, and costs. *Eur Urol Focus* 2017;3:18-26. <https://doi.org/10.1016/j.euf.2017.04.001>
4. Innes G, McRae A, Grafstein E, et al. Variability of renal colic management and outcomes in two Canadian cities. *Can J Emerg Med* 2018;20:702-12. <https://doi.org/10.1017/cem.2018.31>
5. Dauw CA, Kaufman SR, Hollenbeck BK, et al. Expulsive therapy vs. early endoscopic stone removal in patients with acute renal colic: A comparison of indirect costs. *J Urol* 2014;191:673-7. <https://doi.org/10.1016/j.juro.2013.09.028>
6. Ordon M, Andonian S, Blew B, et al. CUA guideline: Management of ureteral calculi. *J Can Urol Assoc* 2015;9:E837-51. <https://doi.org/10.5489/cuaj.3483>
7. Howick J, Chalmers I, Glasziou P, et al. The Oxford Levels of Evidence 2. Published 2011. Available at: <https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebml-levels-of-evidence>. Accessed August 21, 2021
8. Skolarikos A, Laguna MP, Alivizatos G, et al. The role for active monitoring in urinary stones: A systematic review. *J Endourol* 2010;24:923-30. <https://doi.org/10.1089/end.2009.0670>
9. Dellabella M, Milanese G, Muzzonigro G. Randomized trial of the efficacy of tamsulosin, nifedipine, and phloroglucinol in medical expulsive therapy for distal ureteral calculi. *J Urol* 2005;174:167-72. <https://doi.org/10.1097/01.ju.0000161600.54732.86>
10. Ye Z, Yang H, Li H, et al. A multicentre, prospective, randomized trial: Comparative efficacy of tamsulosin and nifedipine in medical expulsive therapy for distal ureteric stones with renal colic. *BJU Int* 2011;108:276-9. <https://doi.org/10.1111/j.1464-410X.2010.09801.x>
11. Pickard R, Starr K, MacLennan G, et al. Medical expulsive therapy in adults with ureteric colic: A multicenter, randomized, placebo-controlled trial. *Lancet* 2015;386:341-9. [https://doi.org/10.1016/S0140-6736\(15\)60933-3](https://doi.org/10.1016/S0140-6736(15)60933-3)
12. Borofsky MS, Walter D, Shah O, et al. Surgical decompression is associated with decreased mortality in patients with sepsis and ureteral calculi. *J Urol* 2013;189:946-51. <https://doi.org/10.1016/j.juro.2012.09.088>
13. Haas CR, Smigelski M, Sebesta EM, et al. Implementation of a hospital-wide protocol reduces time to decompression and length of stay in patients with stone-related obstructive pyelonephritis with sepsis. *J Endourol* 2021;35:77-83. <https://doi.org/10.1089/end.2020.0626>
14. Varda B, Sood A, Krishna N, et al. National rates and risk factors for stent failure after successful insertion in patients with obstructed, infected upper tract stones. *Can Urol Assoc J* 2015;9:E164-71. <https://doi.org/10.5489/cuaj.2456>
15. Mokhmali H, Braun PM, Martinez Portillo FJ, et al. Percutaneous nephrostomy vs. ureteral stents for diversion of hydronephrosis caused by stones: A prospective, randomized clinical trial. *J Urol* 2001;165:1088-92. [https://doi.org/10.1016/S0022-5347\(05\)66434-8](https://doi.org/10.1016/S0022-5347(05)66434-8)
16. Pearle MS, Pierce HL, Miller GL, et al. Optimal method of urgent decompression of the collecting system for obstruction and infection due to ureteral calculi. *J Urol* 1998;160:1260-4. [https://doi.org/10.1016/S0022-5347\(01\)62511-4](https://doi.org/10.1016/S0022-5347(01)62511-4)
17. Christoph F, Weikert S, Müller M, et al. How septic is urosepsis? Clinical course of infected hydronephrosis and therapeutic strategies. *World J Urol* 2005;23:243-7. <https://doi.org/10.1007/s00345-005-0002-x>
18. Ramsey S, Robertson A, Ablett MJ, et al. Evidence-based drainage of infected hydronephrosis secondary to ureteric calculi. *J Endourol* 2010;24:185-9. <https://doi.org/10.1089/end.2009.0361>
19. Yoshimura K, Utsunomiya N, Ichioka K, et al. Emergency drainage for urosepsis associated with upper urinary tract calculi. *J Urol* 2005;173:458-62. <https://doi.org/10.1097/01.ju.0000150512.40102.bb>
20. Shi YF, Ju WL, Zhu YP, et al. The impact of ureteral stent indwelling time on the treatment of acute infection caused by ureteral calculi. *Urolithiasis* 2017;45:579-83. <https://doi.org/10.1007/s00240-017-0964-3>
21. Singer M, Deutschman CS, Seymour C, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). *JAMA* 2016;315:801-10. <https://doi.org/10.1001/jama.2016.0287>
22. Jennings CA, Khan Z, Sidhu P, et al. Management and outcome of obstructive ureteral stones in the emergency department: Emphasis on urine tests and antibiotics usage. *Am J Emerg Med* 2019;37:1855-9. <https://doi.org/10.1016/j.ajem.2018.12.046>



23. Kim HY, Choe HS, Lee DS, et al. Transient renal impairment in the absence of pre-existing chronic kidney disease in patients with unilateral ureteric stone impaction. *Urolithiasis* 2017;45:249-54. <https://doi.org/10.1007/s00240-016-0904-7>
24. Guercio S, Ambu A, Mangione F, et al. Randomized prospective trial comparing immediate versus delayed ureteroscopy for patients with ureteral calculi and normal renal function who present to the emergency department. *J Endourol* 2011;25:1137-41. <https://doi.org/10.1089/end.2010.0554>
25. Kumar A, Mohanty NK, Jain M, et al. A prospective randomized comparison between early (<48 hours of onset of colicky pain) versus delayed shockwave lithotripsy for symptomatic upper ureteral calculi: A single-center experience. *J Endourol* 2010;24:2059-66. <https://doi.org/10.1089/end.2010.0066>
26. Uguz S, Senkul T, Soydan H, et al. Immediate or delayed SWL in ureteric stones: A prospective and randomized study. *Urol Res* 2012;40:739-44. <https://doi.org/10.1007/s00240-012-0490-2>
27. Westphalen AC, Hsia RY, Maselli JH, et al. Radiological imaging of patients with suspected urinary tract stones: National trends, diagnoses, and predictors. *Acad Emerg Med* 2011;18:699-707. <https://doi.org/10.1111/j.1553-2712.2011.01103.x>
28. Chang HC, Raskolnikov D, Dai JC, et al. national imaging trends in nephrolithiasis – does renal ultrasound in the emergency department pave the way for computerized tomography? *Urol Pract* 2021;8:82-7. <https://doi.org/10.1097/UPJ.0000000000000148>
29. Innes GD, Scheuermeyer FX, Law MR, et al. Sex-related differences in emergency department renal colic management: Females have fewer computed tomography scans but similar outcomes. *Acad Emerg Med* 2016;23:1153-60. <https://doi.org/10.1111/acem.13041>
30. Schoenfeld EM, Pekow PS, Shieh MS, et al. The diagnosis and management of patients with renal colic across a sample of us hospitals: High CT utilization despite low rates of admission and inpatient urologic intervention. *PLoS One* 2017;12:e0169160. <https://doi.org/10.1371/journal.pone.0169160>
31. Smith-Bindman R, Aubin C, Boilitz J, et al. Ultrasonography versus computed tomography for suspected nephrolithiasis. *N Engl J Med* 2014;371:1100-10. <https://doi.org/10.1056/NEJMoa1404446>
32. Ripollés T, Agramunt M, Errando J, et al. Suspected ureteral colic: Plain film and sonography vs. unenhanced helical CT: A prospective study in 66 patients. *Eur Radiol* 2004;14:129-36. <https://doi.org/10.1007/s00330-003-1924-6>
33. Foell K, Ordon M, Ghiculete D, et al. Does baseline radiography of the kidneys, ureters, and bladder help facilitate stone management in patients presenting to the emergency department with renal colic? *J Endourol* 2013;27:1425-30. <https://doi.org/10.1089/end.2013.0183>
34. Gervaise A, Naulet P, Beuret F, et al. Low-dose CT with automatic tube current modulation, adaptive statistical iterative reconstruction, and low tube voltage for the diagnosis of renal colic: Impact of body mass index. *Am J Roentgenol* 2014;202:553-60. <https://doi.org/10.2214/AJR.13.11350>
35. McLaughlin PD, Mallinson P, Lourenco P, et al. Dual-energy computed tomography: Advantages in the acute setting. *Radial Clin North Am* 2015;53:619-38. <https://doi.org/10.1016/j.rcl.2015.02.016>
36. Sur RL, Shore N, L'Esperance J, et al. Silodosin to facilitate passage of ureteral stones: A multi-institutional, randomized, double-blinded, placebo-controlled trial. *Eur Urol* 2015;67:959-64. <https://doi.org/10.1016/j.eururo.2014.10.049>
37. Furryk JS, Chu K, Banks C, et al. Distal ureteric stones and tamsulosin: A double-blind, placebo-controlled, randomized, multicenter trial. *Ann Emerg Med* 2016;67:86-95.e2. <https://doi.org/10.1016/j.annemergmed.2015.06.001>
38. Cui Y, Chen J, Zeng F, et al. Tamsulosin as a medical expulsive therapy for ureteral stones: A systematic review and meta-analysis of randomized controlled trials. *J Urol* 2019;201:950-5. <https://doi.org/10.1097/JU.000000000000029>
39. Hollingsworth JM, Canales BK, Rogers MAM, et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. *BMJ* 2016;355:i6112. <https://doi.org/10.1136/bmj.i6112>
40. Amer T, Osman B, Johnstone A, et al. Medical expulsive therapy for ureteric stones: Analyzing the evidence from systematic reviews and meta-analysis of powered double-blinded randomized controlled trials. *Arab J Urol* 2017;15:83-93. <https://doi.org/10.1016/j.aju.2017.03.005>
41. Ye Z, Zeng G, Yang H, et al. Efficacy and safety of tamsulosin in medical expulsive therapy for distal ureteral stones with renal colic: A multicenter, randomized, double-blind, placebo-controlled trial [figure presented]. *Eur Urol* 2018;73:385-91. <https://doi.org/10.1016/j.eururo.2017.10.033>
42. Türk C, Knoll T, Seitz C, et al. Medical expulsive therapy for ureterolithiasis: The EAU recommendations in 2016. *Eur Urol* 2017;71:504-7. <https://doi.org/10.1016/j.eururo.2016.07.024>
43. Campschroer T, Zhu X, Vermooij RWM, et al. Alpha-blockers as medical expulsive therapy for ureteral stones. *Cochrane Database Syst Rev* 2018;4:CD008509. <https://doi.org/10.1002/14651858.CD008509.pub3>
44. Rui P, Santo L, Ashman JJ. Trends in opioids prescribed at discharge from emergency departments among adults: United States, 2006–2017. *Natl Heal Stat Rep* 2020;135:1-12. <https://pubmed.ncbi.nlm.nih.gov/32510308/>
45. Pathan SA, Mitra B, Straney LD, et al. Delivering safe and effective analgesia for management of renal colic in the emergency department: A double-blind, multigroup, randomized controlled trial. *Lancet* 2016;387:1999-2007. [https://doi.org/10.1016/S0140-6736\(16\)00652-8](https://doi.org/10.1016/S0140-6736(16)00652-8)
46. Minhaj FS, Hoang-Nguyen M, Tenney A, et al. Evaluation of opioid requirements in the management of renal colic after guideline implementation in the emergency department. *Am J Emerg Med* 2020;38:2564-9. <https://doi.org/10.1016/j.ajem.2019.12.042>
47. Leapman MS, Derycke E, Skanderson M, et al. Variation in national opioid prescribing patterns following surgery for kidney stones. *Pain Med (United States)* 2018;19:S12-8. <https://doi.org/10.1093/pm/pny125>
48. Taenzler P, Melzack R, Jeans ME. Influence of psychological factors on postoperative pain, mood, and analgesic requirements. *Pain* 1986;24:331-42. [https://doi.org/10.1016/0304-3959\(86\)90119-3](https://doi.org/10.1016/0304-3959(86)90119-3)
49. Worster AS, Bhanich Supapol W. Fluids and diuretics for acute ureteric colic. *Cochrane Database Syst Rev* 2012:CD004926. <https://doi.org/10.1002/14651858.CD004926.pub3>
50. Meltzer AC, Burrows PK, Kirkali Z, et al. Accuracy of patient reported stone passage for patients with acute renal colic treated in the emergency department. *Urology* 2020;136:70-4. <https://doi.org/10.1016/j.urology.2019.10.010>
51. McLarty R, Assmus M, Senthilselvan A, et al. Patient reported outcomes predicting spontaneous stone passage may not have acceptable accuracy. *J Urol* 2020;204:524-30. <https://doi.org/10.1097/JU.0000000000001030>
52. Cheng RZ, Shkolyar E, Chang TC, et al. Ultra-low-dose CT: An effective followup imaging modality for ureterolithiasis. *J Endourol* 2020;34:139-44. <https://doi.org/10.1089/end.2019.0574>
53. Horne KL, Packington R, Monaghan J, et al. Three-year outcomes after acute kidney injury: Results of a prospective parallel group cohort study. *BMJ Open* 2017;7:e015316. <https://doi.org/10.1136/bmjopen-2016-015316>
54. Meldrum KK. Pathophysiology of urinary tract obstruction. *Campbell-Walsh Urology* 2015:1101-1102.
55. Saw KC, Lingemann JE. Lesson 20: Management of calyceal stones. 1999:154–9.
56. Gupta NP, Ansari MS, Kesarvani P, et al. Role of computed tomography with no contrast medium enhancement in predicting the outcome of extracorporeal shockwave lithotripsy for urinary calculi. *BJU Int* 2005;95:1285-8. <https://doi.org/10.1111/j.1464-410X.2005.05520.x>
57. Joseph P, Mandal AK, Singh SK, et al. Computerized tomography attenuation value of renal calculus: can it predict successful fragmentation of the calculus by extracorporeal shockwave lithotripsy? A preliminary study. *J Urol* 2002;167:1968-71. [https://doi.org/10.1016/S0022-5347\(05\)65064-1](https://doi.org/10.1016/S0022-5347(05)65064-1)
58. Abdelhamid M, Mosharafa AA, Ibrahim H, et al. A prospective evaluation of high-resolution CT parameters in predicting extracorporeal shockwave lithotripsy success for upper urinary tract calculi. *J Endourol* 2016;30:1227-32. <https://doi.org/10.1089/end.2016.0364>
59. El-Nahas AR, El-Assmy AM, Mansour O, et al. A prospective multivariate analysis of factors predicting stone disintegration by extracorporeal shockwave lithotripsy: The value of high-resolution non-contrast computed tomography. *Eur Urol* 2007;51:1688-94. <https://doi.org/10.1016/j.eururo.2006.11.048>
60. Ouzaid I, Al-Qahtani S, Dominique S, et al. A 970 Hounsfield units (HU) threshold of kidney stone density on non-contrast computed tomography (NCT) improves patients' selection for extracorporeal shockwave lithotripsy (ESWL): Evidence from a prospective study. *BJU Int* 2012;110:E38-42. <https://doi.org/10.1111/j.1464-410X.2012.10964.x>
61. Yamashita S, Kohjimoto Y, Iguchi T, et al. Variation coefficient of stone density: A novel predictor of the outcome of extracorporeal shockwave lithotripsy. *J Endourol* 2017;31:384-90. <https://doi.org/10.1089/end.2016.0719>
62. Perks AE, Schuler TD, Lee J, et al. Stone attenuation and skin-to-stone distance on computed tomography predicts for stone fragmentation by shockwave lithotripsy. *Urology* 2008;72:765-9. <https://doi.org/10.1016/j.urology.2008.05.046>
63. Wiesenthal JD, Ghiculete D, D'A Honey RJ, et al. Evaluating the importance of mean stone density and skin-to-stone distance in predicting successful shockwave lithotripsy of renal and ureteric calculi. *Urol Res* 2010;38:307-13. <https://doi.org/10.1007/s00240-010-0295-0>
64. Pareek G, Hedian SP, Lee FT, et al. Shockwave lithotripsy success determined by skin-to-stone distance on computed tomography. *Urology* 2005;66:941-4. <https://doi.org/10.1016/j.urology.2005.05.011>
65. Müllhaupt G, Engeler DS, Schmid HP, et al. How do stone attenuation and skin-to-stone distance in computed tomography influence the performance of shockwave lithotripsy in ureteral stone disease? *BMC Urol* 2015;15:72. <https://doi.org/10.1186/s12894-015-0069-7>
66. Wiesenthal JD, Ghiculete D, Ray AA, et al. A clinical nomogram to predict the successful shockwave lithotripsy of renal and ureteral calculi. *J Urol* 2011;186:556-62. <https://doi.org/10.1016/j.juro.2011.03.109>
67. Patel T, Kozakowski K, Hruby G, et al. Skin to stone distance is an independent predictor of stone-free status following shockwave lithotripsy. *J Endourol* 2009;23:1383-5. <https://doi.org/10.1089/end.2009.0394>
68. McAteer JA, Evan AR, Williams JC, et al. Treatment protocols to reduce renal injury during shockwave lithotripsy. *Curr Opin Urol* 2009;19:192-5. <https://doi.org/10.1097/MOU.0b013e32831e16e3>
69. Lambert EH, Walsh R, Moreno MW, et al. Effect of escalating versus fixed voltage treatment on stone comminution and renal injury during extracorporeal shockwave lithotripsy: A prospective randomized trial. *J Urol* 2010;183:580-4. <https://doi.org/10.1016/j.juro.2009.10.025>

70. Willis LR, Evan AP, Connors BA, et al. Prevention of lithotripsy-induced renal injury by pre-treating kidneys with low-energy shockwaves. *J Am Soc Nephrol* 2006;17:663-73. <https://doi.org/10.1681/ASN.2005060634>
71. Weizer AZ, Zhong P, Preminger GM. new concepts in shockwave lithotripsy. *Urol Clin North Am* 2007;34:375-82. <https://doi.org/10.1016/j.ucl.2007.07.002>
72. Seemann O, Rassweiler J, Chvapil M, et al. The effect of single shockwaves on the vascular system of artificially perfused rabbit kidneys. *J Stone Dis* 1993;5:172-8.
73. Pace KT, Weir MJ, Tariq N, et al. Low success rate of repeat shockwave lithotripsy for ureteral stones after failed initial treatment. *J Urol* 2000;164:1905-7. [https://doi.org/10.1016/S0022-5347\(05\)66914-5](https://doi.org/10.1016/S0022-5347(05)66914-5)
74. Rassweiler JJ, Knoll T, Köhrmann KU, et al. Shockwave technology and application: An update. *Eur Urol* 2011;59:784-96. <https://doi.org/10.1016/j.euro.2011.02.033>
75. Pace KT, Ghiculete D, Harju M, et al. Shockwave lithotripsy at 60 or 120 shocks per minute: A randomized, double-blind trial. *J Urol* 2005;174:595-9. <https://doi.org/10.1097/01.ju.0000165156.90011.95>
76. Honey RJDA, Schuler TD, Ghiculete D, et al. A randomized, double-blind trial to compare shockwave frequencies of 60 and 120 shocks per minute for upper ureteral stones. *J Urol* 2009;182:1418-23. <https://doi.org/10.1016/j.juro.2009.06.019>
77. Davenport K, Minervini A, Keoghane S, et al. Does rate matter? The results of a randomized controlled trial of 60 vs. 120 shocks per minute for shockwave lithotripsy of renal calculi. *J Urol* 2006;176:2055-8. <https://doi.org/10.1016/j.juro.2006.07.012>
78. Madbouly K, El-Tiraifi AM, Seida M, et al. Slow vs. fast shockwave lithotripsy rate for urolithiasis: A prospective randomized study. *J Urol* 2005;173:127-30. <https://doi.org/10.1097/01.ju.0000147820.36996.86>
79. Yilmaz E, Batislam E, Basar M, et al. Optimal frequency in extracorporeal shockwave lithotripsy: Prospective randomized study. *Urology* 2005;66:1160-4. <https://doi.org/10.1016/j.urol.2005.06.111>
80. Li K, Lin T, Zhang C, et al. Optimal frequency of shockwave lithotripsy in urolithiasis treatment: A systematic review and meta-analysis of randomized controlled trials. *J Urol* 2013;190:1260-7. <https://doi.org/10.1016/j.juro.2013.03.075>
81. Kato Y, Yamaguchi S, Hori J, et al. Improvement of stone comminution by slow delivery rate of shockwaves in extracorporeal lithotripsy. *Int J Urol* 2006;13:1461-5. <https://doi.org/10.1111/j.1442-2042.2006.01609.x>
82. Chacko J, Moore M, Sankey N, et al. Does a slower treatment rate impact the efficacy of extracorporeal shockwave lithotripsy for solitary kidney or ureteral stones? *J Urol* 2006;175:1370-4. [https://doi.org/10.1016/S0022-5347\(05\)00683-X](https://doi.org/10.1016/S0022-5347(05)00683-X)
83. Kang DH, Cho KS, Ham WS, et al. Comparison of high, intermediate, and low frequency shockwave lithotripsy for urinary tract stone disease: Systematic review and network meta-analysis. *PLoS One* 2016;11:e0158661. <https://doi.org/10.1371/journal.pone.0158661>
84. López-Acón JD, Alba AB, Bahilo-Mateu P, et al. Analysis of the efficacy and safety of increasing the energy dose applied per session by increasing the number of shockwaves in extracorporeal lithotripsy: A prospective and comparative study. *J Endourol* 2017;31:1289-94. <https://doi.org/10.1089/end.2017.0261>
85. Budia Alba A, López Acón JD, Polo-Rodrigo A, et al. Analysis of the safety profile of treatment with a large number of shockwaves per session in extracorporeal lithotripsy. *Actas Urol Esp* 2015;39:291-5. <https://doi.org/10.1016/j.acuro.2014.12.001>
86. Eryildirim B, Sahin C, Tuncer M, et al. Medical expulsive therapy following shockwave lithotripsy in ureteral calculi: An effective approach for the improvement of health-related quality of life. *Urol Int* 2016;97:260-5. <https://doi.org/10.1159/000446002>
87. Ahmed A, Shalaby E, El-feky M, et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. *Urol Int* 2016;97:266-72. <https://doi.org/10.1159/000445840>
88. De Nunzio C, Brassetti A, Bellangino M, et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: A short-term followup randomized, placebo-controlled study. *J Endourol* 2016;30:817-21. <https://doi.org/10.1089/end.2016.0113>
89. Schuler TD, Shahani R, Honey RJDA, et al. Medical expulsive therapy as an adjunct to improve shockwave lithotripsy outcomes: A systematic review and meta-analysis. *J Endourol* 2009;23:387-93. <https://doi.org/10.1089/end.2008.0216>
90. Bhagat SK, Chacko NK, Kekre NS, et al. Is there a role for tamsulosin in shockwave lithotripsy for renal and ureteral calculi? *J Urol* 2007;177:2185-8. <https://doi.org/10.1016/j.juro.2007.01.160>
91. Gravina GL, Costa AM, Ronchi P, et al. Tamsulosin treatment increases clinical success rate of single extracorporeal shockwave lithotripsy of renal stones. *Urology* 2005;66:24-8. <https://doi.org/10.1016/j.urol.2005.01.013>
92. Porgiglia F, Destefanis P, Fiori C, et al. Role of adjunctive medical therapy with nifedipine and deflazacort after extracorporeal shockwave lithotripsy of ureteral stones. *Urology* 2002;59:835-8. [https://doi.org/10.1016/S0090-4295\(02\)01553-4](https://doi.org/10.1016/S0090-4295(02)01553-4)
93. Skolarikos A, Grivas N, Kallidonis P, et al. The efficacy of medical expulsive therapy (MET) in improving stone-free rate and stone expulsion time, after extracorporeal shockwave lithotripsy (SWL) for upper urinary stones: A systematic review and meta-analysis. *Urology* 2015;86:1057-64. <https://doi.org/10.1016/j.urol.2015.09.004>
94. Li M, Wang Z, Yang J, et al. Adjunctive medical therapy with indataalpha-blocker after extracorporeal shockwave lithotripsy of renal and ureteral stones: A meta-analysis. *PLoS One* 2015;10. <https://doi.org/10.1371/journal.pone.0122497>
95. Chen K, Mi H, Xu G, et al. The efficacy and safety of tamsulosin combined with extracorporeal shockwave lithotripsy for urolithiasis: A systematic review and meta-analysis of randomized controlled trials. *J Endourol* 2015;29:1166-76. <https://doi.org/10.1089/end.2015.0098>
96. Ouyang W, Sun G, Long G, et al. Adjunctive medical expulsive therapy with tamsulosin for repeated extracorporeal shockwave lithotripsy: A systematic review and meta-analysis. *Int Braz J Urol* 2020;47:23-35. <https://doi.org/10.1590/s1677-5538.ibju.2020.0093>
97. Oestreich MC, Vernooij RW, Sathianathan NJ, et al. Alpha-blockers after shockwave lithotripsy for renal or ureteral stones in adults. *Cochrane Database Syst Rev* 2020;11(11):CD013393. <https://doi.org/10.1002/14651858.CD013393.pub2>
98. Musa AAK. Use of double-J stents prior to extracorporeal shockwave lithotripsy is not beneficial: Results of a prospective randomized study. *Int Urol Nephrol* 2008;40:19-22. <https://doi.org/10.1007/s11255-006-9030-8>
99. Pettenati C, Fegoun AB EI, Hupertan V, et al. Double J stent reduces the efficacy of extracorporeal shockwave lithotripsy in the treatment of lumbar ureteral stones. *Cent Eur J Urol* 2013;66:309-13. <https://doi.org/10.5173/cej.2013.03.art14>
100. Pengfei S, Min J, Jie Y, et al. Use of ureteral stent in extracorporeal shockwave lithotripsy for upper urinary calculi: A systematic review and meta-analysis. *J Urol* 2011;186:1328-35. <https://doi.org/10.1016/j.juro.2011.05.073>
101. Wang H, Man L, Li G, et al. Meta-analysis of stenting vs. non-stenting for the treatment of ureteral stones. *PLoS One* 2017;12:e0167670. <https://doi.org/10.1371/journal.pone.0167670>
102. Sfoungaristos S, Polimeros N, Kavouros A, et al. Stenting or not prior to extracorporeal shockwave lithotripsy for ureteral stones? Results of a prospective randomized study. *Int Urol Nephrol* 2012;44:731-7. <https://doi.org/10.1007/s11255-011-0062-3>
103. Lucio II J, Korkeas F, Lopes-Neto AC, et al. Steinstrasse predictive factors and outcomes after extracorporeal shockwave lithotripsy. *Int Braz J Urol* 2011;37:477-82. <https://doi.org/10.1590/S1677-55382011000400006>
104. Duvdevani M, Lorber G, Gofrit ON, et al. Fever after shockwave lithotripsy-risk factors and indications for prophylactic antimicrobial treatment. *J Endourol* 2010;24:277-81. <https://doi.org/10.1089/end.2009.0283>
105. Assimos D, Krambeck A, Miller NL, et al. Surgical management of stones: American Urological Association/Endourological Society guideline, Part 1. *J Urol* 2016;196:1153-60. <https://doi.org/10.1016/j.juro.2016.05.090>
106. Alsaikhan B, Kozicars A, Lee JY, et al. Preoperative alpha-blockers for ureteroscopy for ureteral stones: A systematic review and meta-analysis of randomized controlled trials. *J Endourol* 2020;34:33-41. <https://doi.org/10.1089/end.2019.0520>
107. Brisbane W, Bailey MR, Sorensen MD. An overview of kidney stone imaging techniques. *Nat Rev Urol* 2016;13:654-62. <https://doi.org/10.1038/nrurol.2016.154>
108. Chew BH, Brotherhood HL, Sur RL, et al. Natural history, complications, and re-intervention rates of asymptomatic residual stone fragments after ureteroscopy: A report from the EDGE research consortium. *J Urol* 2016;195:982-6. <https://doi.org/10.1016/j.juro.2015.11.009>
109. Beiko DT, Beasley KA, Koka PK, et al. Upper tract imaging after ureteroscopic holmium:YAG laser lithotripsy: When is it necessary? *Can J Urol* 2003;10:2062-7.
110. Sutherland TN, Pearle MS, Lotan Y. How much is a kidney worth? Cost-effectiveness of routine imaging after ureteroscopy to prevent silent obstruction. *J Urol* 2013;189:2136-41. <https://doi.org/10.1016/j.juro.2012.12.059>
111. Weizer AZ, AUGE BK, Silverstein AD, et al. Routine postoperative imaging is important after ureteroscopic stone manipulation. *J Urol* 2002;168:46-50. <https://doi.org/10.1097/00005392-200207000-00013>
112. May PC, Hsi RS, Tran H, et al. The morbidity of ureteral strictures in patients with prior ureteroscopic stone surgery: Multi-institutional outcomes. *J Endourol* 2018;32:309-14. <https://doi.org/10.1089/end.2017.0657>
113. Traxer O, Thomas A. Prospective evaluation and classification of ureteral wall injuries resulting from insertion of a ureteral access sheath during retrograde intrarenal surgery. *J Urol* 2013;189:580-4. <https://doi.org/10.1016/j.juro.2012.08.197>

114. Traxer O, Wendt-Nordahl G, Sodha H, et al. Differences in renal stone treatment and outcomes for patients treated either with or without the support of a ureteral access sheath: The Clinical Research Office of the Endourological Society Ureteroscopy global study. *World J Urol* 2015;33:2137-44. <https://doi.org/10.1007/s00345-015-1582-8>
115. Huang J, Zhao Z, AlSmadi JK, et al. Use of the ureteral access sheath during ureteroscopy: A systematic review and meta-analysis. *PLoS One* 2018;13:e0193600. <https://doi.org/10.1371/journal.pone.0193600>
116. De Coninck V, Keller EX, Rodríguez-Mansalve M, et al. Systematic review of ureteral access sheaths: facts and myths. *BJU Int* 2018;122:959-69. <https://doi.org/10.1111/bju.14389>
117. Stern KL, Loftus CJ, Doizi S, et al. A prospective study analyzing the association between high-grade ureteral access sheath injuries and the formation of ureteral strictures. *J Urol* 2019;202:454. <https://doi.org/10.1016/j.jurology.2019.02.032>
118. Cetti RJ, Biers S, Keoghane SR. The difficult ureter: what is the incidence of pre-stenting? *Ann R Coll Surg Engl* 2011;93:31-3. <https://doi.org/10.1308/003588411X12851639106990>
119. Assimos D, Crisci A, Culkin D, et al. Preoperative JJ stent placement in ureteric and renal stone treatment: Results from the Clinical Research Office of Endourological Society (CROES) ureteroscopy (URS) global study. *BJU Int* 2016;117:648-54. <https://doi.org/10.1111/bju.13250>
120. Jessen JP, Breda A, Brehmer M, et al. International collaboration in endourology: Multicenter evaluation of pre-stenting for ureterorenoscopy. *J Endourol* 2016;30:268-73. <https://doi.org/10.1089/end.2015.0109>
121. Netsch C, Knipper S, Bach T, et al. Impact of preoperative ureteral stenting on stone-free rates of ureteroscopy for nephroureterolithiasis: A matched-paired analysis of 286 patients. *Urology* 2012;80:1214-20. <https://doi.org/10.1016/j.jurology.2012.06.064>
122. Chu L, Farris CA, Corcoran AT, et al. Preoperative stent placement decreases cost of ureteroscopy. *Urology* 2011;78:309-13. <https://doi.org/10.1016/j.jurology.2011.03.055>
123. Chu L, Sternberg KM, Averch TD. Preoperative stenting decreases operative time and re-operative rates of ureteroscopy. *J Endourol* 2011;25:751-4. <https://doi.org/10.1089/end.2010.0400>
124. Pengfei S, Yutao L, Jie Y, et al. The results of ureteral stenting after ureteroscopic lithotripsy for ureteral calculi: A systematic review and meta-analysis. *J Urol* 2011;186:1904-9. <https://doi.org/10.1016/j.juro.2011.06.066>
125. Ordonez M, Hwang EC, Borofsky M, et al. Ureteral stent vs. no ureteral stent for ureteroscopy in the management of renal and ureteral calculi. *Cochrane Database Syst Rev* 2019;2019:CD012703. <https://doi.org/10.1002/14651858.CD012703.pub2>
126. Pais VM, Smith RE, Stedina EA, et al. Does omission of ureteral stents increase risk of unplanned return visit? A systematic review and meta-analysis. *J Urol* 2016;196:1458-66. <https://doi.org/10.1016/j.juro.2016.05.109>
127. Mittakanti HR, Conti SL, Pao AC, et al. Unplanned emergency department visits and hospital admissions following ureteroscopy: do ureteral stents make a difference? *Urology* 2018;117:44-9. <https://doi.org/10.1016/j.jurology.2018.03.019>
128. Torricelli FC, De S, Hinck B, et al. Flexible ureteroscopy with a ureteral access sheath: When to stent? *Urology* 2014;83:278-81. <https://doi.org/10.1016/j.jurology.2013.10.002>
129. Rapoport D, Perks AE, Teichman JMH. Ureteral access sheath use and stenting in ureteroscopy: Effect on unplanned emergency room visits and cost. *J Endourol* 2007;21:993-7. <https://doi.org/10.1089/end.2006.0236>
130. Cevik I, Dillioglugil O, Akdas A, et al. Is stent placement necessary after uncomplicated ureteroscopy for removal of impacted ureteral stones? *J Endourol* 2010;24:1263-7. <https://doi.org/10.1089/end.2009.0153>
131. Denstedt JD, Wollin TA, Sofer M, et al. A prospective randomized controlled trial comparing non-stented vs. stented ureteroscopic lithotripsy. *J Urol* 2001;165:1419-22. [https://doi.org/10.1016/S0022-5347\(05\)66320-3](https://doi.org/10.1016/S0022-5347(05)66320-3)
132. Damiano R, Autorino R, De Sio M, et al. Effect of tamsulosin in preventing ureteral stent-related morbidity: A prospective study. *J Endourol* 2008;22:651-5. <https://doi.org/10.1089/end.2007.0257>
133. El-Nahas AR, Tharwat M, Elsaadany M, et al. A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent-related symptoms. *World J Urol* 2016;34:963-8. <https://doi.org/10.1007/s00345-015-1704-3>
134. Lallas CD, Auge BK, Raj GV, et al. Laser Doppler flowmetric determination of ureteral blood flow after ureteral access sheath placement. *J Endourol* 2002;16:583-90. <https://doi.org/10.1089/089277902320913288>
135. Paul CJ, Brooks NA, Ghareeb GM, et al. pilot study to determine optimal stent duration following ureteroscopy: Three vs. seven days. *Curr Urol* 2017;11:97-102. <https://doi.org/10.1159/000447201>
136. Kumar A, Nanda B, Kumar N, et al. A prospective randomized comparison between shockwave lithotripsy and semirigid ureteroscopy for upper ureteral stones <2 cm: A single-center experience. *J Endourol* 2015;29:47-51. <https://doi.org/10.1089/end.2012.0493>
137. Scotland KB, Safaee Ardekani G, Chan JYH, et al. Total surface area influences stone-free outcomes in shockwave lithotripsy for distal ureteral calculi. *J Endourol* 2019;33:661-6. <https://doi.org/10.1089/end.2019.0120>
138. Hautmann S, Friedrich MG, Fernandez S, et al. Extracorporeal shockwave lithotripsy compared with ureteroscopy for the removal of small distal ureteral stones. *Urol Int* 2004;73:238-43. <https://doi.org/10.1159/000080834>
139. Verze P, Imbimbo C, Cangelmo G, et al. Extracorporeal shockwave lithotripsy vs. ureteroscopy as first-line therapy for patients with single, distal ureteric stones: A prospective randomized study. *BJU Int* 2010;106:1748-52. <https://doi.org/10.1111/j.1464-410X.2010.09338.x>
140. Matlaga BR, Jansen JP, Meckley LM, et al. Treatment of ureteral and renal stones: A systematic review and meta-analysis of randomized, controlled trials. *J Urol* 2012;188:130-7. <https://doi.org/10.1016/j.juro.2012.02.2569>
141. Drake T, Grivas N, Dabestani S, et al. What are the benefits and harms of ureteroscopy compared with shockwave lithotripsy in the treatment of upper ureteral stones? A systematic review. *Eur Urol* 2017;72:772-86. <https://doi.org/10.1016/j.euro.2017.04.016>
142. Rebeck DA, Coleman S, Chen JF, et al. Extracorporeal shockwave lithotripsy vs. ureteroscopy: A comparison of intraoperative radiation exposure during the management of nephrolithiasis. *J Endourol* 2012;26:597-601. <https://doi.org/10.1089/end.2011.0185>
143. Cone EB, Pareek G, Ursiny M, et al. Cost-effectiveness comparison of ureteral calculi treated with ureteroscopic laser lithotripsy vs. shockwave lithotripsy. *World J Urol* 2017;35:161-6. <https://doi.org/10.1007/s00345-016-1842-2>
144. Constanti M, Calvert RC, Thomas K, et al. Cost analysis of ureteroscopy (URS) vs. extracorporeal shockwave lithotripsy (ESWL) in the management of ureteric stones <10 mm in adults: A U.K. perspective. *BJU Int* 2020;125:457-66. <https://doi.org/10.1111/bju.14938>
145. Penniston KL, Nakada SY. Health-related quality of life differs between male and female stone formers. *J Urol* 2007;178:2435-40. <https://doi.org/10.1016/j.juro.2007.08.009>
146. Diniz DHMP, Bloy SL, Schor N. Quality of life of patients with nephrolithiasis and recurrent painful renal colic. *Nephron Clin Pract* 2007;106. <https://doi.org/10.1159/000102995>
147. Bensalah K, Tuncel A, Gupta A, et al. Determinants of quality of life for patients with kidney stones. *J Urol* 2008;179:2238-43. <https://doi.org/10.1016/j.juro.2008.01.116>
148. Donnally CJ, Gupta A, Bensalah K, et al. Longitudinal evaluation of the SF-36 quality of life questionnaire in patients with kidney stones. *Urol Res* 2011;39:141-6. <https://doi.org/10.1007/s00240-010-0313-2>
149. Bryant M, Angell J, Tu H, et al. Health-related quality of life for stone formers. *J Urol* 2012;188:436-40. <https://doi.org/10.1016/j.juro.2012.04.015>
150. Chandrasekar T, Monga M, Nguyen M, et al. Internet-based patient survey on urolithiasis treatment and patient satisfaction. *J Endourol* 2015;29:725-9. <https://doi.org/10.1089/end.2014.0643>
151. Park J, Shin DW, Chung JH, et al. Shockwave lithotripsy versus ureteroscopy for ureteral calculi: A prospective assessment of patient-reported outcomes. *World J Urol* 2013;31:1569-74. <https://doi.org/10.1007/s00345-012-0966-2>
152. Lee JH, Woo SH, Kim ET, et al. Comparison of patient satisfaction with treatment outcomes between ureteroscopy and shockwave lithotripsy for proximal ureteral stones. *Korean J Urol* 2010;51:788-93. <https://doi.org/10.4111/kju.2010.51.11.788>
153. Ghalayini IF, Al-Ghazo MA, Khader YS. Extracorporeal shockwave lithotripsy vs. ureteroscopy for distal ureteric calculi: efficacy and patient satisfaction. *Int Braz J Urol* 2006;32:656-64. <https://doi.org/10.1590/S1677-55382006000600006>
154. Rabah DM, Alomar M, Binsaleh S, et al. Health-related quality of life in ureteral stone patients: Post-ureterolithiasis. *Urol Res* 2011;39:385-8. <https://doi.org/10.1007/s00240-011-0375-9>
155. Izamin I, Aniza I, Rizal AM, et al. Comparing extracorporeal shockwave lithotripsy and ureteroscopy for treatment of proximal ureteric calculi: A cost-effectiveness study. *Med J Malaysia* 2009;64:12-21. <https://pubmed.ncbi.nlm.nih.gov/19852314/>
156. Hamamoto S, Unno R, Taguchi K, et al. Determinants of health-related quality of life for patients after urinary lithotripsy: Ureteroscopic vs. shockwave lithotripsy. *Urolithiasis* 2018;46:203-10. <https://doi.org/10.1007/s00240-017-0972-3>
157. Ceylan Y, Ucer O, Bozkurt O, et al. The effect of SWL and URS on health-related quality of life in proximal ureteral stones. *Minim Invasive Ther Allied Technol* 2018;27:148-52. <https://doi.org/10.1080/13645706.2017.1350719>
158. Raja A, Hekmati Z, Joshi HB. How do urinary calculi influence health-related quality of life and patient treatment preference: A systematic review. *J Endourol* 2016;30:727-43. <https://doi.org/10.1089/end.2016.0110>

**Correspondence:** Dr. Jason Y. Lee, Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada; [jasonleeuoft@gmail.com](mailto:jasonleeuoft@gmail.com)